Founded in 2003, Endosense develops and commercialises solutions to enable the adoption of percutaneous catheter ablation (PCA) for the treatment of atrial fibrillation (AF).

With 6 million patients impacted, AF is the most prevalent cardiac rhythm disorder in which the upper chambers of the heart beat ineffectively due to abnormal electrical activity. The company’s lead product is a force sensor catheter, TactiCath™, which measures the force the catheter exerts on the beating heart wall. TactiCath™ has the potential to increase the effectiveness and the safety profile of PCA.

Print this page